Key Details
Price
$0.17Annual ROE
-101.04%Beta
1.41Events Calendar
Next earnings date:
Feb 13, 2025Recent quarterly earnings:
Dec 17, 2024Recent annual earnings:
Dec 17, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Apr 25, 2024Analyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
Applied DNA Sciences (APDN) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $5.20 per share a year ago.
Is the next pandemic here. With health officials declaring Monkeypox a public health emergency, investors need to be watching Monkeypox-related stocks.
Applied DNA Sciences, Inc. (NASDAQ:APDN ) Q3 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Corporate Participants Sanjay Hurry - Head of IR Beth Jantzen - Chief Financial Officer Jim Hayward - Chairman, President and Chief Executive Officer Clay Shorrock - Chief Legal Officer and Head of Business Development Conference Call Participants Operator Good day, and welcome to the Applied DNA Fiscal Third Quarter 2024 Investor Conference Call. All participants will be listen-only mode.
Applied DNA Sciences (APDN) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of a loss of $0.64 per share. This compares to loss of $4.80 per share a year ago.
Applied DNA Sciences (APDN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
STONY BROOK, NY / ACCESSWIRE / May 13, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA) and the Institute of Hematology and Blood Transfusion (ÚHKT/IHBT) have announced that an abstract on the development of an enzymatic, non-viral manufacturing workflow for efficient production of clinical-grade CAR T-cell therapies has been accepted for presentation at the European Hematology Association 2024 Hybrid Congress in Madrid, Spain from June 13 - 16, 2024. The accepted abstracts will be available on the Congress' website from May 14, 2024.
Here is how Applied DNA Sciences (APDN) and Encore Wire (WIRE) have performed compared to their sector so far this year.
Applied DNA Sciences, Inc. (APDN) Q1 2024 Earnings Call Transcript
Applied DNA Sciences (APDN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.14 per share a year ago.
STONY BROOK, NY / ACCESSWIRE / February 5, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its first quarter fiscal 2024 financial results after market close on Thursday, February 8, 2024. In conjunction with this announcement, Applied DNA management will host a conference call for analysts and members of the investment community starting at 4:30 p.m.
FAQ
- What is the ticker symbol for Applied DNA Sciences?
- Does Applied DNA Sciences pay dividends?
- What sector is Applied DNA Sciences in?
- What industry is Applied DNA Sciences in?
- What country is Applied DNA Sciences based in?
- When did Applied DNA Sciences go public?
- Is Applied DNA Sciences in the S&P 500?
- Is Applied DNA Sciences in the NASDAQ 100?
- Is Applied DNA Sciences in the Dow Jones?
- When was Applied DNA Sciences's last earnings report?
- When does Applied DNA Sciences report earnings?
- Should I buy Applied DNA Sciences stock now?